Business Wire·Nov 9, 2026, 4:05 PM ET

Hyperfine, Inc. Reports Third Quarter 2026 Financial Results

HYPR

Hyperfine, Inc. reported record third quarter 2026 revenue of $6.0 million, a 73% increase from the same period in 2025.
Gross profit reached a record $3.4 million with a 57% gross margin, while operating loss narrowed to $7.3 million.
Net cash burn was $5.6 million, the lowest quarterly figure to date, marking the first time quarterly revenue exceeded net cash burn.
The company sold 14 commercial Swoop® systems in Q3 2026, a 75% increase compared to 8 units sold in Q3 2025.
Management expects full-year 2026 revenue to be between $20 million and $22 million, representing 55% growth at the midpoint.
Expected full-year 2026 net cash burn is projected between $26 million and $28 million, a 10% decline at the midpoint.
Enrollment in the Contrast PMR study was completed, with an FDA submission expected by the end of 2026 to expand system labeling.
The Swoop® Model 2 system launched in Europe and the UK following regulatory markings, with exclusive distributor agreements signed for Kuwait and the UAE.
FDA clearance was received for the latest Optive AI™ software, which includes improved noise correction, guided scanning, and an isotropic T1 sequence.
NEURO PMR study results published in the Journal of Neuroimaging showed 92% concordance between portable MRI and high-field MRI in blinded reviews.
Cash and cash equivalents totaled $37.9 million as of September 30, 2026, with no financing proceeds generated during the quarter.
A new Form S-3 registration statement is expected to be filed to register an aggregate offering amount of $150 million.
A conference call to discuss Q3 2026 results is scheduled for November 9, 2026, at 1:30 p.m. PT.